• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021

    7/29/21 4:15:00 PM ET
    $FLXN
    Major Pharmaceuticals
    Health Care
    Get the next $FLXN alert in real time by email

    BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET.

    A live webcast of the conference call can be accessed through the "Investors" tab on the Flexion Therapeutics website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference call is 855-770-0022 for domestic participants and 908-982-4677 for international participants, with Conference ID # 3846257. Please dial in at least 15 minutes in advance to ensure a timely connection to the call.

    About Flexion Therapeutics

    Flexion Therapeutics (NASDAQ:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com.

    Contact:

    Scott Young

    Vice President, Corporate Communications & Investor Relations

    T: 781-305-7194

    [email protected]



    Primary Logo

    Get the next $FLXN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLXN

    DatePrice TargetRatingAnalyst
    11/19/2021Outperform → Market Perform
    Northland Capital Markets
    10/19/2021$25.00 → $10.00Buy → Neutral
    HC Wainwright & Co.
    10/12/2021$20.00 → $12.00Outperform → Market Perform
    BMO Capital
    10/12/2021Strong Buy → Market Perform
    Raymond James
    10/12/2021$14.00 → $10.00Outperform → Neutral
    Credit Suisse
    8/6/2021$8.00 → $6.00Neutral
    Goldman Sachs
    8/5/2021$20.00 → $18.00Buy
    Needham
    More analyst ratings